Ann: Quarterly Report and Appendix 4C, page-79

Not sure what "rubbish figures" I am supposed to be quoting?

Stock is capped at ~$150m - fact (100m shares * $1.50)
Bell Potter in their report have $2m-$4m EBITDA in FY19 - Fact
Colorado Cultivators are the key supplier of hemp in Nth America (section 9.6.2.1 of prospectus), and the contract is due to expire July 15 2018 - Fact
Tiverton Agriculture is the main supplier in Australia - Fact

EXL takes supply of such product and processes it into oil and food based hemp products - Fact

So the much hoped Medical Cannabis license is based on "expertise" in growing crops they don't grow!

At the prospectus, Elixinol was sold into EXL for $64.6m ($58m goodwill and 30x EBITDA).
Hemp Foods was sold in for $5.2m ($4.1m goodwill) and no earnings
Elixinol Aust was sold in at $12.3m ($9.7m goodwill) with no license, no revenue and 1 employee!
That's a total of $82m ($72m goodwill), than add $20 raise to get $100m

So tell me why the business should now be valued at $150m....

No agenda - just a warning